1. Home
  2. RLMD vs GAIN Comparison

RLMD vs GAIN Comparison

Compare RLMD & GAIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$6.93

Market Cap

752.1M

Sector

Health Care

ML Signal

HOLD

Logo Gladstone Investment Corporation Business Development Company

GAIN

Gladstone Investment Corporation Business Development Company

HOLD

Current Price

$15.88

Market Cap

653.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
RLMD
GAIN
Founded
2004
2005
Country
United States
United States
Employees
N/A
70
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
752.1M
653.5M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
RLMD
GAIN
Price
$6.93
$15.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$12.40
$14.75
AVG Volume (30 Days)
869.6K
400.9K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
9.19%
EPS Growth
45.28
N/A
EPS
N/A
N/A
Revenue
$13,070.00
N/A
Revenue This Year
N/A
$9.07
Revenue Next Year
N/A
$7.32
P/E Ratio
N/A
$4.38
Revenue Growth
154.83
N/A
52 Week Low
$0.52
$13.14
52 Week High
$8.00
$17.14

Technical Indicators

Market Signals
Indicator
RLMD
GAIN
Relative Strength Index (RSI) 45.89 47.06
Support Level $6.81 $15.78
Resistance Level $7.46 $17.04
Average True Range (ATR) 0.42 0.61
MACD -0.04 -0.12
Stochastic Oscillator 50.17 50.71

Price Performance

Historical Comparison
RLMD
GAIN

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

About GAIN Gladstone Investment Corporation Business Development Company

Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.

Share on Social Networks: